Ultra-powerful 7T MRI scanners could be used to help identify those patients with Parkinson’s disease and similar conditions most likely to benefit from new treatments for previously-untreatable symptoms, say scientists.
People with Parkinson’s disease and their doctors confront many unknowns, including the answer to exactly how deep brain stimulation (DBS) relieves some of the motor symptoms patients experience.
Exercise increases levels of a chemical involved in brain cell growth, which bolsters the release of the “feel good” hormone dopamine, a new study shows. Dopamine is known to play a key role in movement, motivation, and learning.
It’s often said that a little stress can be good for you. Now scientists have shown that the same may be true for cells, uncovering a newly-discovered mechanism that might help prevent the build-up of tangles of proteins commonly seen in dementia.
The neurotransmitter dopamine, famous for its role in reward, is also involved in recognizing emotions, according to new research published in JNeurosci.
This research in mice provides evidence for how dynamics in the default mode network of the brain are altered by activating the locus coeruleus region – a small nucleus in the brainstem that releases norepinephrine. It also suggests new targets for treatment to restore DMN function.
UTHealth Houston’s Movement Disorders and Neurodegenerative Diseases Fellowship Training Program (UTMOVE fellowship program) has been chosen by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) as one of eight international academic centers to train a new movement disorder clinician-researcher — a neurologist with additional training and expertise in diagnosing and treating Parkinson’s and related diseases — as part of the Edmond J. Safra Fellowship in Movement Disorders Class of 2025.
The Center of Excellence for Parkinson’s Disease & Related Disorders, King Chulalongkorn Memorial Hospital has launched PDPlus application to help Parkinson’s patients record their symptoms in real-time and send them reminders for their medications. PD Plus App also has motor coordination evaluation games, and reporting system to connect with doctors for close monitoring.
Parkinson's Disease Awareness month is dedicated to raising awareness and support for patients suffering from this progressive brain disorder. Learn more about Parkinson's disease, treatment options and support for those with Parkinson's.
Older adults who take statin drugs for cholesterol may have a reduced risk of developing parkinsonism, a neurological condition that causes movement issues such as tremor, according to a recent study by researchers at Rush University Medical Center.
Here are some of the latest articles that have been added to the Clinical Trials channel on Newswise.
“Our team of neurologists and specialized therapists identified the need to help people diagnosed with Parkinson’s disease who are not acutely ill or severely disabled but who struggle greatly at home with the symptoms and life-style changes that Parkinson’s disease brings,” said Sara Cuccurullo, M.D., vice president and medical director, JFK Johnson Rehabilitation Institute. “In our new program, patients are admitted from their homes to participate in an individualized, multidisciplinary and targeted two-week inpatient rehabilitation program that helps them restore and maintain their function.”
Researchers have engineered probiotic bacteria that can synthesize the dopamine precursor L-DOPA, a powerful mainstay treatment for Parkinson’s disease. Preclinical tests show that the new treatment approach is not only safe and well-tolerated but also eliminates side effects that eventually develop when L-DOPA is taken orally.
Embargoed press materials are now available for the Experimental Biology (EB) 2022 meeting, featuring cutting-edge research from across the life sciences. EB 2022, to be held April 2–5 in Philadelphia, is the annual meeting of five scientific societies bringing together thousands of scientists and 25 guest societies in one interdisciplinary community.
Reporters are invited to join a live discussion of research announcements at the forefront of the life sciences during a virtual press conference for the Experimental Biology (EB) 2022 meeting. The press conference will be held online from 11–11:45 a.m. Eastern on Friday, April 1, 2022 (RSVP by Thursday, March 31).
Researchers describe a mechanism in mice that underlies local dopamine release in the brain
Professor Emeritus Moussa Youdim is the recipient of the 2022 Israel Prize for Life Sciences. He is co-developer of the Parkinson's disease drug Azilect (Rasagiline), and was selected for the Israel Prize "for his pioneering, groundbreaking scientific achievements in the field of neuropharmacology."
Parkinsonism is a term for a group of neurological conditions that cause movement problems including tremors, slowed movement and stiffness, with Parkinson’s disease being one of the better knowns causes. A new study suggests that older people taking statin drugs have a lower chance of developing parkinsonism later compared to people who were not taking statins. The research is published in the March 23, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology. Statins are drugs used to lower cholesterol in the blood and protect against atherosclerosis, a buildup of plaque in the arteries that can lead to hardening of the arteries, heart attack and stroke.
Scientists at La Jolla Institute for Immunology (LJI) have found that people with Parkinson's disease have a clear "genetic signature" of the disease in their memory T cells. The scientists hope that targeting these genes may open the door to new Parkinson's treatments and diagnostics.
People living with neurological or psychiatric conditions may have an increased likelihood of having a second such condition in the future, and their sex influences their risk, according to new research.
The 147th Annual Meeting of the American Neurological Association (taking place in-person October 22–25, 2022 in Chicago) will explore new frontiers in neurology, including climate change and the brain, lab-grown brain structures for studying disease, and addressing disparities in neurologic care.
Don't miss these articles in our Staff Picks channel
FDA Approval of Focused Ultrasound Device Provides Patients with Novel Treatment Option Without Requiring Incision.
The research may also advance understanding of the biochemical roots of Parkinson’s disease and other synucleinopathies, which affect more than 6.8 million Americans.
The Latest Research News in Cardiovascular Health
People who have had a heart attack may be slightly less likely than people in the general population to develop Parkinson’s disease later in life, according to new research published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.
ISU researchers are embarking on an in-depth and comprehensive study to determine the underlying mechanisms by which singing can improve breathing and swallowing for people with Parkinson’s disease. The researchers will also track changes to brain activity and biomarkers of stress and inflammation to better understand how the social benefits of singing with others can slow the disease’s progression and its symptoms.
Scientists have successfully tested in the lab a tiny biosensor they developed that can detect biomarkers tied to traumatic brain injuries.
A five-year, $3.2 million grant from the National Institutes of Health will help a research team including faculty at Binghamton University, State University of New York explore serotonin's role in Parkinson's disease.
University of Maryland School of Medicine researchers developed a technique in laboratory animals to consistently and reproducibly open the blood-brain barrier. Their paper essentially provides a roadmap for other researchers to develop and test new therapies for brain diseases.
A new study shows that people with Parkinson’s disease who eat a diet that includes three or more servings per week of foods high in flavonoids, like tea, apples, berries and red wine, may have a lower chance of dying during the study period than people who do not eat as many flavonoids. The research is published in the January 26, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study looked at several types of flavonoids and found that higher consumption of flavan-3-ols and anthocyanins, both before and after a Parkinson’s diagnosis, was associated with lower risk of death during the study period.
Here are some of the latest articles we've posted in the Behavioral Science channel.
The latest research news from the Health Disparities Channel.
New pose estimation software has the potential to help neurologists and their patients capture important clinical data using simple tools such as smartphones and tablets, according to a study by Johns Hopkins Medicine...
Researchers in a multi-institution study led by UCLA Health call for more research as well as customized treatments, education and support to empower women living with Parkinson’s disease to address their unmet medical needs.
Irvine, Calif., Jan. 19, 2022 — A team of University of California, Irvine researchers has discovered a possible reason why L-dopa, the front-line drug for treating Parkinson’s disease, loses efficacy and causes dyskinesia – involuntary, erratic muscle movements of the patient’s face, arms, legs and torso – as treatment progresses.
CLEVELAND: Cleveland Clinic has launched a landmark study to better understand why millions of people around the world suffer from brain diseases, with the goal of pinpointing disease biomarkers early, well before clinical symptoms present themselves. The new Cleveland Clinic Brain Study – the largest clinical study ever for brain disease – will collect data from up to 200,000 neurologically healthy individuals over a 20-year period to identify brain disease biomarkers and targets for preventing and curing neurological disorders.
A new study suggests that people with early-stage Parkinson’s disease who regularly got one to two hours of moderate exercise twice a week, like walking or gardening, may have less trouble balancing, walking and doing daily activities later. The research is published in the January 12, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology. Researchers found that those who exercised regularly over five years did better on cognitive tests and had slower progression of the disease in several aspects.
Mount Sinai researchers analyzed thousands of microglia from different brain regions of deceased patients who had been diagnosed with a variety of neuropsychiatric and neurodegenerative disorders. Their results, published in Nature Genetics, support the idea that microglia may play critical roles in some cases of brain disease while also providing a potentially valuable guide for future studies.
Researchers reporting in ACS Chemical Neuroscience have shown that, at least in the test tube, the SARS-CoV-2 N-protein interacts with a neuronal protein called α-synuclein and speeds the formation of amyloid fibrils, pathological protein bundles that have been implicated in Parkinson’s disease.
UC San Diego School of Medicine partners with The Michael J. Fox Foundation on a clinical study to identify biomarkers of Parkinson’s disease. The study seeks to recruit 4,000 participants by the end of 2023.
A new study from Texas Biomedical Research Institute (Texas Biomed) and collaborators has identified a promising drug candidate to minimize uncontrolled, erratic muscle movements, called dyskinesia, associated with Parkinson’s disease.
Isaacson will lead an academic clinical research program aimed at reducing the risk of Alzheimer’s disease (AD), Parkinson’s disease, and Lewy body dementia in individuals with a family history of these diseases who do not yet have any cognitive decline or other clinical complaints.
The American Academy of Neurology (AAN) has issued a guideline providing recommendations for treating movement symptoms, called motor symptoms, in people with early Parkinson’s disease. The guideline is published in the November 15, 2021, online issue of Neurology®, the medical journal of the AAN, and is endorsed by the Parkinson’s Foundation. This guideline updates recommendations on dopaminergic medications that were published in the 2002 AAN guideline on the initiation of treatment for Parkinson’s disease.
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson’s disease. The finding could help explain an earlier outcome of the same study, in which the drug nilotinib was able to halt motor and non-motor (cognition and quality of life) decline in the long term.
“Announcement of the November 2021 issue of Neurosurgical Focus.”
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
